Docoh
Loading...

CLDX Celldex Therapeutics

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Company profile

Ticker
CLDX
Exchange
CEO
Anthony Marucci
Employees
Incorporated
Location
Fiscal year end
Former names
AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
SEC CIK
IRS number
133191702

CLDX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

29 Mar 21
18 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 43.84M 43.84M 43.84M 43.84M 43.84M 43.84M
Cash burn (monthly) (positive/no burn) (positive/no burn) 8.26M 5.28M 1.74M 3.37M
Cash used (since last report) n/a n/a 29.79M 19.04M 6.26M 12.14M
Cash remaining n/a n/a 14.05M 24.8M 37.57M 31.69M
Runway (months of cash) n/a n/a 1.7 4.7 21.6 9.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 Dec 20 Wright Richard M. Common Stock Sell Dispose S No No 18.6065 9,375 174.44K 208
14 Dec 20 Wright Richard M. Common Stock Option exercise Aquire M No No 2.78 9,375 26.06K 9,583
14 Dec 20 Wright Richard M. Common Stock Sell Dispose S No No 18.6065 11,457 213.17K 208
14 Dec 20 Wright Richard M. Common Stock Option exercise Aquire M No No 9.0165 11,457 103.3K 11,665
14 Dec 20 Wright Richard M. Incentive Stock Option Common Stock Option exercise Dispose M No No 2.78 9,375 26.06K 20,625
14 Dec 20 Wright Richard M. Incentive Stock Option Common Stock Option exercise Dispose M No No 9.0165 11,457 103.3K 6,876
18 Jun 20 Shoos Karen L. NQSO Common Stock Grant Aquire A No No 10.38 11,000 114.18K 11,000
18 Jun 20 Penner Harry JR NQSO Common Stock Grant Aquire A No No 10.38 11,000 114.18K 11,000
18 Jun 20 Pepin Ronald Incentive Stock Option Common Stock Grant Aquire A No No 10.38 14,400 149.47K 14,400

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

92.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 127 90 +41.1%
Opened positions 53 36 +47.2%
Closed positions 16 18 -11.1%
Increased positions 32 25 +28.0%
Reduced positions 24 13 +84.6%
13F shares
Current Prev Q Change
Total value 644.99M 470.29M +37.1%
Total shares 36.81M 31.71M +16.1%
Total puts 408.6K 205.2K +99.1%
Total calls 592.8K 454.3K +30.5%
Total put/call ratio 0.7 0.5 +52.6%
Largest owners
Shares Value Change
RTW Investments 3.42M $59.97M +9.7%
Redmile 2.71M $47.51M +36.3%
Adage Capital Partners GP, L.L.C. 2.5M $43.8M +22.0%
Eventide Asset Managment 1.84M $32.19M +262.9%
STT State Street 1.81M $31.72M +7030.7%
Vanguard 1.77M $30.97M +2.6%
Acuta Capital Partners 1.63M $28.51M +5.3%
Citadel Advisors 1.4M $24.47M +5453.0%
Ikarian Capital 1.36M $23.92M -7.1%
Vivo Capital 1.29M $22.63M -25.0%
Largest transactions
Shares Bought/sold Change
BVF 0 -3.07M EXIT
STT State Street 1.81M +1.78M +7030.7%
Citadel Advisors 1.4M +1.37M +5453.0%
Eventide Asset Managment 1.84M +1.33M +262.9%
POLR Polar Capital 0 -1.25M EXIT
Logos Global Management 0 -1.2M EXIT
Octagon Capital Advisors 1.04M +1.04M NEW
Marshall Wace North America 1.28M +1.03M +403.1%
Polar Capital 1M +1M NEW
Redmile 2.71M +722.42K +36.3%

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Academy, accuracy, Aid, al, allergic, allosteric, amplifying, Answer, Anthony, antihistamine, asymptomatic, Bartlett, breaking, bridging, Brownlie, carryback, Cavanaugh, Chair, Chancery, cholinergic, circulating, cold, ColdU, compelling, Complaint, Connemara, Conrad, contact, contending, context, count, Counterclaim, covenant, Crowley, cultural, cutoff, dealing, declaratory, dermatologic, DermNet, dermographism, description, Diane, downregulated, duly, EAACI, Elizabeth, enzyme, epinephrine, essence, Exhibit, featured, forward, Freddy, FricTest, Germany, Gilead, hallmark, hard, Harry, Hautarzt, hemoglobin, Herbert, herewith, HIV, immunosuppression, immunosuppressive, Importantly, Interferon, intervention, intravenously, isolated, itch, itching, Jimenez, Jr, Karen, Keith, led, Linkbase, Margo, Marino, Marucci, mirror, move, neuroinflammation, neutrophil, NIH, notification, omitted, onsite, ophthalmic, Org, overdosage, pancreatic, Penner, pharmacodynamic, PK, plasma, PN, President, profound, proper, properly, provocation, prurigo, pruritic, pts, reaction, repetition, resolved, respiratory, Richard, ROW, Rule, Sarah, SBIR, SCCHN, schema, SD, Senior, sensory, serum, shaking, Shareholder, shipment, shortly, situation, spontaneously, SRS, summer, Sunshine, sweating, synthesized, Taxonomy, temperature, TGFb, thereunto, TME, tryptase, undersigned, unjust, untreated, Verified, Vice, week, Weller, white, Wright, XBRL, Young
Removed: added, aimed, American, animal, appealed, ASCO, breast, carcinoma, CBR, CT, cytotoxic, death, developmental, diarrhea, DOR, enhance, ensuing, epitope, Erbitux, evolution, formation, Frontier, gastric, HPV, hyperproliferative, IAVI, inhibition, inInternal, kill, liver, lowered, mechanism, median, medimmune, melanoma, modulation, newly, objective, opposition, oral, ORR, OS, ourin, packaged, PFS, pharmacologic, poor, post, provisional, rash, registering, regulating, release, renal, resistance, reversal, Salk, Simon, slower, supplemental, thyroid, tiered, unclear